Drug Patents Expiring in 2032

1. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same Jun, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ABRAXANE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393318 ABRAXIS BIOSCIENCE Methods of treating cancer Mar, 2032

(9 years from now)

US9597409 ABRAXIS BIOSCIENCE Methods of treating cancer Mar, 2032

(9 years from now)

US9393318

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer Sep, 2032

(9 years from now)

US9597409

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer Sep, 2032

(9 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

3. Drug name - ACETADOTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof Apr, 2032

(9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6GM/30ML (200MG/ML) INJECTABLE;INTRAVENOUS Prescription

4. Drug name - ADZENYS ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709491 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles Jun, 2032

(9 years from now)

US9017731 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles Jun, 2032

(9 years from now)

US9265737 NEOS THERAPS INC Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles Jun, 2032

(9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1.25MG BASE/ML SUSPENSION, EXTENDED RELEASE;ORAL Discontinued

5. Drug name - ADZENYS XR-ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017731 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles Jun, 2032

(9 years from now)

US9265737 NEOS THERAPS Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles Jun, 2032

(9 years from now)

US8709491 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles Jun, 2032

(9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 3.1MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 6.3MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 9.4MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 12.5MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 15.7MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 18.8MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription

6. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jan, 2032

(9 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Feb, 2032

(9 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jul, 2032

(9 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jul, 2032

(9 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

7. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(9 years from now)

US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(9 years from now)

US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

CN106986822B HELSINN HLTHCARE Substituted 4-Phenylpyridine For The Treatment Of Nk-1 Receptor Related Diseases
Nov, 2032

(10 years from now)

CN106518924B HELSINN HLTHCARE 4 For Treating Substituted-Phenyl Pyridine Nk-1 Receptor Associated Diseases
Nov, 2032

(10 years from now)

CN106518924A HELSINN HLTHCARE For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases
Nov, 2032

(10 years from now)

CN106986822A HELSINN HLTHCARE For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases
Nov, 2032

(10 years from now)

IN201404907P4 HELSINN HLTHCARE Substituted-4- Phenyl Pyridines For The Treatment Of Nk 1 Receptor Related Diseases
Nov, 2032

(10 years from now)

IN324179B HELSINN HLTHCARE Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases
Nov, 2032

(10 years from now)

EP2785706A1 HELSINN HLTHCARE Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases.
Nov, 2032

(10 years from now)

EP2785706B1 HELSINN HLTHCARE Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases.
Nov, 2032

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator May, 2032

(9 years from now)

US8895586 HELSINN HLTHCARE Methods of treating emesis May, 2032

(9 years from now)

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL POWDER;INTRAVENOUS Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

8. Drug name - ALECENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound Mar, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Prescription

9. Drug name - ALIQOPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(9 years from now)

CN103649091A BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

CN103649091B BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

EP2694508A1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

EP2694508B1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts Mar, 2032

(9 years from now)

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/VIAL POWDER;INTRAVENOUS Prescription

10. Drug name - ALKINDI SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740 ETON Treatment of adrenal insufficiency Nov, 2032

(10 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG GRANULE;ORAL Prescription
1MG GRANULE;ORAL Prescription
2MG GRANULE;ORAL Prescription
5MG GRANULE;ORAL Prescription

11. Drug name - APTIOM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750747 SUNOVION PHARMS INC Treatments involving eslicarbazepine acetate or eslicarbazepine Aug, 2032

(9 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

12. Drug name - ARISTADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters Mar, 2032

(9 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters Nov, 2032

(10 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
441MG/1.6ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
662MG/2.4ML (275.83MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
882MG/3.2ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1064MG/3.9ML (272.82MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

13. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jan, 2032

(9 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Feb, 2032

(9 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jul, 2032

(9 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jul, 2032

(9 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

14. Drug name - AVYCAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

CN105294690A ALLERGAN The Preparation Comprises -7 - Oxo -6-(Sulfo-Oxy) -1, 6-Diazabicyclo [3 2 1] Octane - -2 - Formamide Heterocyclic Compound And Salt Thereof
Jun, 2032

(9 years from now)

CN103649051A ALLERGAN Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof
Jun, 2032

(9 years from now)

CN103649051B ALLERGAN Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof
Jun, 2032

(9 years from now)

CN105294690B ALLERGAN Preparation Comprising Anti - -7 - Oxo - -6-(Sulfo Group) -1, 6-Di-Aza-Bicyclo (3, 2, 1] -2 - Formamide Heterocyclic Compound And Its Salt Method
Jun, 2032

(9 years from now)

EP2721005B1 ALLERGAN Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof
Jun, 2032

(9 years from now)

EP2721005A1 ALLERGAN Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof
Jun, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5GM BASE;2GM/VIAL POWDER;INTRAVENOUS Prescription

15. Drug name - AZSTARYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same Jul, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5.2MG BASE;EQ 26.1MG BASE CAPSULE;ORAL Prescription
EQ 7.8MG BASE;EQ 39.2MG BASE CAPSULE;ORAL Prescription
EQ 10.4MG BASE;EQ 52.3MG BASE CAPSULE;ORAL Prescription

16. Drug name - BELBUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief Dec, 2032

(10 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 0.075MG BASE FILM;BUCCAL Prescription
EQ 0.15MG BASE FILM;BUCCAL Prescription
EQ 0.3MG BASE FILM;BUCCAL Prescription
EQ 0.45MG BASE FILM;BUCCAL Prescription
EQ 0.6MG BASE FILM;BUCCAL Prescription
EQ 0.75MG BASE FILM;BUCCAL Prescription
EQ 0.9MG BASE FILM;BUCCAL Prescription

17. Drug name - BIJUVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639375 THERAPEUTICSMD INC Progesterone formulations Nov, 2032

(10 years from now)

US10206932 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US8846649 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US8846648 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US9114146 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US9114145 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US10675288 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US9301920 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US11033626 THERAPEUTICSMD INC Progesterone formulations having a desirable pk profile Nov, 2032

(10 years from now)

US9006222 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US10806740 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US11103513 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US8933059 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US8633178 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US8987237 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US8993549 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US11103516 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US11166963 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US10052386 THERAPEUTICSMD INC Progesterone formulations Nov, 2032

(10 years from now)

US8993548 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

US11110099 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies Nov, 2032

(10 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG;100MG CAPSULE;ORAL Prescription
1MG;100MG CAPSULE;ORAL Prescription

18. Drug name - BIKTARVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

EP2744810B1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

EP2744810A1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE;120MG;EQ 15MG BASE TABLET;ORAL Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE TABLET;ORAL Prescription

19. Drug name - BORTEZOMIB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations Nov, 2032

(10 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
3.5MG/VIAL POWDER;INTRAVENOUS Prescription

20. Drug name - BRAFTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate Nov, 2032

(10 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate Nov, 2032

(10 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate Nov, 2032

(10 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued
75MG CAPSULE;ORAL Prescription

21. Drug name - BUNAVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.1MG BASE;EQ 0.3MG BASE FILM;BUCCAL Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE FILM;BUCCAL Discontinued
EQ 6.3MG BASE;EQ 1MG BASE FILM;BUCCAL Discontinued

22. Drug name - CALDOLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation Mar, 2032

(9 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation Mar, 2032

(9 years from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
400MG/4ML (100MG/ML) SOLUTION;INTRAVENOUS Discontinued
800MG/8ML (100MG/ML) SOLUTION;INTRAVENOUS Prescription
800MG/200ML (4MG/ML) SOLUTION;INTRAVENOUS Prescription

23. Drug name - CALQUENCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

CN103889987A ASTRAZENECA As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide
Jul, 2032

(9 years from now)

CN106243113A ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN103889987B ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN106243113B ASTRAZENECA As A Selective Btk Inhibitor And Pyrazine
Jul, 2032

(9 years from now)

EP3689878B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP3689878A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors Jul, 2032

(9 years from now)

Drugs and Companies using ACALABRUTINIB ingredient

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

24. Drug name - CASPOFUNGIN ACETATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations Dec, 2032

(10 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription
70MG/VIAL POWDER;INTRAVENOUS Prescription

25. Drug name - CETYLEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427421 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine May, 2032

(9 years from now)

US9561204 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine May, 2032

(9 years from now)

US8747894 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine May, 2032

(9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage
Strength Dosage Availability
2.5GM TABLET, EFFERVESCENT;ORAL Discontinued
500MG TABLET, EFFERVESCENT;ORAL Discontinued

26. Drug name - COMETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717720 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Feb, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

27. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression Jan, 2032

(9 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

28. Drug name - COPIKTRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(9 years from now)

CN103648499B SECURA Preparation Method For Isoquinoline Ketone And Solid Form Of Isoquinoline Ketone
Jan, 2032

(9 years from now)

CN103648499A SECURA Preparation Method For Isoquinoline Ketone And Solid Form Of Isoquinoline Ketone
Jan, 2032

(9 years from now)

EP3238722B1 SECURA Solid Forms Of Isoquinolinones
Jan, 2032

(9 years from now)

EP2663309A1 SECURA Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones
Jan, 2032

(9 years from now)

EP2663309B1 SECURA Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones
Jan, 2032

(9 years from now)

EP3238722A1 SECURA Solid Forms Of Isoquinolinones
Jan, 2032

(9 years from now)

EP2663309A4 SECURA Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones
Jan, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof Jan, 2032

(9 years from now)

Drugs and Companies using DUVELISIB ingredient

Treatment: For the treatment of patients with follicular lymphoma (fl); for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG CAPSULE;ORAL Prescription
25MG CAPSULE;ORAL Prescription

29. Drug name - COTEMPLA XR-ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089496 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles Jun, 2032

(9 years from now)

US9072680 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles Jun, 2032

(9 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8.6MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
17.3MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
25.9MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription

30. Drug name - CYCLOSET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688094 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

US8613947 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

US11000522 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

US9700555 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

US9993474 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

US9192576 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

US9522117 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

US8431155 VEROSCIENCE Bromocriptine formulations Apr, 2032

(9 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2 and 3; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4 and 5; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7, 8, and 9; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4, 5, and 6; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7 and 8; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10 and 11; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16, 17, and 18; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13 and 14; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10, 11, and 12; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16 and 17; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13, 14, and 15; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28 and 29; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25 and 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 22, 23, and 24; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19 and 20; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19, 20, and 21; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28, 29, and 30; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25, 26, and 27; Improvement of glycemic control in individuals with type 2 diabetes; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 11; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13 and 23; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 11, and 12; adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 23, and 24; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41, 52, and 53; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66, 75, and 76; adjunct to diet and execrise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29, 39, and 40; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 13, and 14; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54 and 64; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29 and 39; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 13; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66 and 75; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41 and 52; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89, 99, and 100; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54, 64, and 65; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15, 27, and 28; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15 and 27; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77 and 87; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89 and 99; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77, 87, and 88; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43, 50 and 51; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1,10 and 11; adjunct to diet and excercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30, 41, and 42; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1 and 10; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30 and 41; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21 and 28; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12 and 19; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43 and 50; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12, 19 and 20; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, and 29; Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient; improvement of glycemic control in individuals with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.8MG BASE TABLET;ORAL Prescription

31. Drug name - DEFITELIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide Jun, 2032

(9 years from now)

US11085043 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide Jun, 2032

(9 years from now)

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/2.5ML (80MG/ML) SOLUTION;INTRAVENOUS Prescription

32. Drug name - DESCOVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

EP2744810B1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

EP2744810A1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
120MG;EQ 15MG BASE TABLET;ORAL Prescription
200MG;EQ 25MG BASE TABLET;ORAL Prescription

33. Drug name - DETECTNET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors Aug, 2032

(9 years from now)

US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors Aug, 2032

(9 years from now)

US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors Aug, 2032

(9 years from now)

Drugs and Companies using COPPER DOTATATE CU-64 ingredient

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
4mL (1mCi/ML) SOLUTION;INTRAVENOUS Prescription

34. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy Mar, 2032

(9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

35. Drug name - DEXYCU KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799642 EYEPOINT PHARMS Dose guides for injection syringe May, 2032

(9 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: NA

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage
Strength Dosage Availability
9% SUSPENSION;INTRAOCULAR Prescription

36. Drug name - DILAUDID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container Apr, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
0.2MG/ML INJECTABLE;INJECTION Prescription
1MG/ML INJECTABLE;INJECTION Prescription
2MG/ML INJECTABLE;INJECTION Prescription
4MG/ML INJECTABLE;INJECTION Discontinued
10MG/ML INJECTABLE;INJECTION Discontinued
250MG/VIAL INJECTABLE;INJECTION Discontinued

37. Drug name - DUZALLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;200MG TABLET;ORAL Discontinued
300MG;200MG TABLET;ORAL Discontinued

38. Drug name - EPANED KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8568747 SILVERGATE PHARMS Enalapril compositions Nov, 2032

(10 years from now)

US8778366 SILVERGATE PHARMS Enalapril compositions Nov, 2032

(10 years from now)

US9968553 SILVERGATE PHARMS Enalapril compositions Nov, 2032

(10 years from now)

US9855214 SILVERGATE PHARMS Enalapril compositions Nov, 2032

(10 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Treatment: Treatment of hypertension; method of treatment of heart failure; method of treating hypertension; treatment of heart failure; method of treating left ventricular dysfunction; Method of treatment of heart failure; treatment of hypertension; method of treating left ventricular dysfunction; method of treating hypertension; treatment of heart failure

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
1MG/ML FOR SOLUTION;ORAL Discontinued

39. Drug name - EPCLUSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

CN103328480A GILEAD SCIENCES INC A Imidazole Imidazole For Condensation Of Antiviral Composition
Nov, 2032

(10 years from now)

CN105837584A GILEAD SCIENCES INC Condensed Imidazolyl-Imidazole As Antiviral Compound
Nov, 2032

(10 years from now)

CN105837584B GILEAD SCIENCES INC Condensation Of Imidazole Imidazole As Antivirus Compound
Nov, 2032

(10 years from now)

CN103328480B GILEAD SCIENCES INC Condensed Imidazolyl-Imidazole As Antiviral Compound
Nov, 2032

(10 years from now)

EP2907816A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2635588A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP3431477B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2907816B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP3431477A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2635588B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;37.5MG/PACKET PELLETS;ORAL Prescription
200MG;50MG/PACKET PELLETS;ORAL Prescription

40. Drug name - EVOTAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 BRISTOL-MYERS SQUIBB Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE;150MG TABLET;ORAL Prescription

41. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2032

(9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

42. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2032

(9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

43. Drug name - FETZIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8865937 ALLERGAN Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(9 years from now)

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 40MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 80MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 120MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

44. Drug name - FIRDAPSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine Jun, 2032

(9 years from now)

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription

45. Drug name - FIRMAGON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415085 FERRING Method of treating prostate cancer with GnRH antagonist Apr, 2032

(9 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist Apr, 2032

(9 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Treatment: Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 80MG BASE/VIAL POWDER;SUBCUTANEOUS Prescription
EQ 120MG BASE/VIAL POWDER;SUBCUTANEOUS Prescription

46. Drug name - GENVOYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

EP2744810B1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

EP2744810A1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

47. Drug name - GILENYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Mar, 2032

(9 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Sep, 2032

(9 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription

48. Drug name - GONITRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101592 POHL BOSKAMP Stabilized granules containing glyceryl trinitrate Mar, 2032

(9 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Treatment: NA

Dosage: POWDER;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
0.4MG/PACKET POWDER;SUBLINGUAL Discontinued

49. Drug name - HARVONI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456414 GILEAD SCIENCES INC Methods for treating HCV Sep, 2032

(9 years from now)

US9393256 GILEAD SCIENCES INC Methods for treating HCV Sep, 2032

(9 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
33.75MG;150MG/PACKET PELLETS;ORAL Prescription
45MG;200MG/PACKET PELLETS;ORAL Prescription

50. Drug name - ILEVRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921337 NOVARTIS Carboxyvinyl polymer-containing nanoparticle suspensions Mar, 2032

(9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.3% SUSPENSION/DROPS;OPHTHALMIC Prescription

51. Drug name - IMVEXXY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835487 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Nov, 2032

(10 years from now)

US9289382 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Nov, 2032

(10 years from now)

US10806697 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Nov, 2032

(10 years from now)

US11241445 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Nov, 2032

(10 years from now)

US11246875 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Nov, 2032

(10 years from now)

US10537581 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Nov, 2032

(10 years from now)

Drugs and Companies using ESTRADIOL ingredient

Treatment: Treatment of dyspareunia; treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT;VAGINAL

More Information on Dosage
Strength Dosage Availability
0.004MG INSERT;VAGINAL Prescription
0.01MG INSERT;VAGINAL Prescription

52. Drug name - INBRIJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545878 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

US8685442 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

US9393210 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

US8945612 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
42MG POWDER;INHALATION Prescription

53. Drug name - INREBIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391094 IMPACT Compositions and methods for treating myelofibrosis Jun, 2032

(9 years from now)

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription

54. Drug name - IONSYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8781571 THE MEDICINES CO Switch validation circuit and method Mar, 2032

(9 years from now)

US8428708 THE MEDICINES CO Self-test for analgesic product May, 2032

(9 years from now)

US8428709 THE MEDICINES CO Current control for electrotransport drug delivery Jun, 2032

(9 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
EQ 40MCG BASE/ACTIVATION SYSTEM;IONTOPHORESIS, TRANSDERMAL Discontinued

55. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772888 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor Mar, 2032

(9 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription
EQ 600MG BASE TABLET;ORAL Prescription

56. Drug name - JORNAY PM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder Mar, 2032

(9 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
40MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
60MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
80MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
100MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

57. Drug name - KORLYM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842801 CORCEPT THERAP Optimizing mifepristone absorption Nov, 2032

(10 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

58. Drug name - KUVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin Nov, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
100MG/PACKET POWDER;ORAL Prescription
500MG/PACKET POWDER;ORAL Prescription

59. Drug name - LAZANDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731869 BTCP PHARMA Container Jan, 2032

(9 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE SPRAY, METERED;NASAL Prescription
EQ 0.3MG BASE SPRAY, METERED;NASAL Discontinued
EQ 0.4MG BASE SPRAY, METERED;NASAL Prescription

60. Drug name - LEVOTHYROXINE SODIUM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168239 FRESENIUS KABI USA Levothyroxine formulations Aug, 2032

(9 years from now)

US9168238 FRESENIUS KABI USA Levothyroxine formulations Aug, 2032

(9 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations Oct, 2032

(10 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MCG/VIAL POWDER;INTRAVENOUS Prescription
200MCG/VIAL POWDER;INTRAVENOUS Prescription
500MCG/VIAL POWDER;INTRAVENOUS Prescription

61. Drug name - LOKELMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(9 years from now)

EP2673237B1 ASTRAZENECA Use Of A Zirconium Silicate For The Treatment Of Hyperkalemia
Feb, 2032

(9 years from now)

EP2673237A2 ASTRAZENECA Use Of A Zirconium Silicate For The Treatment Of Hyperkalemia
Feb, 2032

(9 years from now)

EP2673237A4 ASTRAZENECA Microporous Zirconium Silicate For The Treatment Of Hyperkalemia
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
5GM/PACKET FOR SUSPENSION;ORAL Prescription
10GM/PACKET FOR SUSPENSION;ORAL Prescription

62. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168556 SUNOVION RESP Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer Sep, 2032

(9 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

63. Drug name - LYBALVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778960 ALKERMES INC Methods for treating antipsychotic-induced weight gain Feb, 2032

(9 years from now)

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 10MG BASE TABLET;ORAL Prescription
10MG;EQ 10MG BASE TABLET;ORAL Prescription
15MG;EQ 10MG BASE TABLET;ORAL Prescription
20MG;EQ 10MG BASE TABLET;ORAL Prescription

64. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(9 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors Jul, 2032

(9 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds Nov, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
50MG;20MG/PACKET PELLETS;ORAL Prescription

65. Drug name - MEKINIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580304 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9271941 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9399021 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9155706 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG TABLET;ORAL Prescription
EQ 1MG TABLET;ORAL Discontinued
EQ 2MG TABLET;ORAL Prescription

66. Drug name - MOVANTIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012469 REDHILL Crystalline naloxol-peg conjugate
Apr, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

67. Drug name - NEOPROFEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415337 RECORDATI RARE Ibuprofen compositions and methods of making same
Mar, 2032

(9 years from now)

Drugs and Companies using IBUPROFEN LYSINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) INJECTABLE;INTRAVENOUS Prescription

68. Drug name - NETSPOT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375498 AAA USA INC Process for the preparation of complexes of 68Ga Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
2.1-5.5mCi/ML POWDER;INTRAVENOUS Prescription

69. Drug name - NEUPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925150 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Mar, 2032

(9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
2MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
3MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
4MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
6MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
8MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

70. Drug name - NUVESSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198858 CHEMO RESEARCH SL Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations Jun, 2032

(9 years from now)

US8946276 CHEMO RESEARCH SL High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis Jun, 2032

(9 years from now)

US10596155 CHEMO RESEARCH SL Aqueous-based metronidazole gel formulations Jun, 2032

(9 years from now)

US10238634 CHEMO RESEARCH SL Aqueous-based metronidazole gel formulations Jun, 2032

(9 years from now)

Drugs and Companies using METRONIDAZOLE ingredient

Treatment: Treatment of bacterial vaginosis with metronidazole gel

Dosage: GEL;VAGINAL

More Information on Dosage
Strength Dosage Availability
1.3% GEL;VAGINAL Prescription

71. Drug name - ODEFSEY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

EP2744810B1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

EP2744810A1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

72. Drug name - OFIRMEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Mar, 2032

(9 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

73. Drug name - OLINVYK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

CN103702561B TREVENA Opioid Receptor Ligands And Methods Of Using And Preparing Method Thereof
Mar, 2032

(9 years from now)

CN103702561A TREVENA Opioid Receptor Ligand, And Use And Preparation Method Thereof
Mar, 2032

(9 years from now)

IN324754B TREVENA An Opioid Receptor Compound
Mar, 2032

(9 years from now)

IN201308346P1 TREVENA Opioid Receptor Ligands And Methods Of Using And Making Same
Mar, 2032

(9 years from now)

EP3290415B1 TREVENA Opioid Receptor Ligands And Methods Of Using And Making Same
Mar, 2032

(9 years from now)

EP2688403B1 TREVENA Opioid Receptor Ligands And Methods Of Using And Making Same
Mar, 2032

(9 years from now)

EP3290415A1 TREVENA Opioid Receptor Ligands And Methods Of Using And Making Same
Mar, 2032

(9 years from now)

EP2688403A1 TREVENA Opioid Receptor Ligands And Methods Of Using And Making Same
Mar, 2032

(9 years from now)

EP2688403A4 TREVENA Opioid Receptor Ligands And Methods Of Using And Making Same
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same Mar, 2032

(9 years from now)

Drugs and Companies using OLICERIDINE ingredient

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1MG/ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription
2MG/2ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription
30MG/30ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription

74. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(10 years from now)

IN201401357P3 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

IN326913B NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O- Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

EP2791134B1 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

EP2791134A1 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

75. Drug name - OXBRYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(10 years from now)

US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(10 years from now)

US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(10 years from now)

CN104135859B GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

CN104135859A GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

CN107176953A GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

CN107176953B GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

IN322527B GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP2797416A1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP3141542B1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP2797416B1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP2797416A4 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP3141542A1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin Dec, 2032

(10 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
500MG TABLET;ORAL Prescription

76. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen Feb, 2032

(9 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

77. Drug name - PATADAY ONCE DAILY RELIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9533053 ALCON LABS INC High concentration olopatadine ophthalmic composition May, 2032

(9 years from now)

US8791154 ALCON LABS INC High concentration olopatadine ophthalmic composition May, 2032

(9 years from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.7% BASE SOLUTION/DROPS;OPHTHALMIC Over the counter

78. Drug name - PEPAXTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285946 ONCOPEPTIDES AB Lyophilized preparations of melphalan flufenamide Apr, 2032

(9 years from now)

US10869928 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides Apr, 2032

(9 years from now)

US10322182 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides Apr, 2032

(9 years from now)

US10543274 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides Apr, 2032

(9 years from now)

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/VIAL POWDER;INTRAVENOUS Discontinued

79. Drug name - PLENVU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780112 SALIX Colonoscopy-preparation Mar, 2032

(9 years from now)

US10792306 SALIX Colonoscopy—preparation Mar, 2032

(9 years from now)

US10646512 SALIX Colonoscopy - preparation Mar, 2032

(9 years from now)

US9592252 SALIX Colonoscopy—preparation Aug, 2032

(9 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM FOR SOLUTION;ORAL Prescription

80. Drug name - PONVORY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(9 years from now)

Drugs and Companies using PONESIMOD ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

81. Drug name - PRECEDEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455527 HOSPIRA Methods of treatment using a dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US8338470 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US9320712 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US10016396 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US8242158 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US9616049 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US8648106 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US9320712

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US9616049

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US8648106

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US8242158

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US8455527

(Pediatric)

HOSPIRA Methods of treatment using a dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US8338470

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription

82. Drug name - PREZCOBIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;800MG TABLET;ORAL Prescription

83. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jan, 2032

(9 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

84. Drug name - PROAIR HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH AEROSOL, METERED;INHALATION Prescription

85. Drug name - PROLENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085958 BAUSCH AND LOMB Bromfenac bioavailability Nov, 2032

(10 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.07% ACID SOLUTION/DROPS;OPHTHALMIC Prescription

86. Drug name - PYRUKYND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy May, 2032

(9 years from now)

US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy May, 2032

(9 years from now)

US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy May, 2032

(9 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy Oct, 2032

(10 years from now)

Drugs and Companies using MITAPIVAT SULFATE ingredient

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription

87. Drug name - QINLOCK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461179 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases Jun, 2032

(9 years from now)

Drugs and Companies using RIPRETINIB ingredient

Treatment: Treatment of gastrointestinal stromal tumor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription

88. Drug name - QULIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

89. Drug name - QVAR 40

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.04MG/INH AEROSOL, METERED;INHALATION Discontinued
0.08MG/INH AEROSOL, METERED;INHALATION Discontinued

90. Drug name - QVAR REDIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 NORTON WATERFORD Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.04MG/INH AEROSOL, METERED;INHALATION Prescription
0.08MG/INH AEROSOL, METERED;INHALATION Prescription

91. Drug name - RAVICTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326966 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Mar, 2032

(9 years from now)

US8404215 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging Mar, 2032

(9 years from now)

US9095559 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Mar, 2032

(9 years from now)

US9254278 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Mar, 2032

(9 years from now)

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage: LIQUID;ORAL

More Information on Dosage
Strength Dosage Availability
1.1GM/ML LIQUID;ORAL Prescription

92. Drug name - RESTASIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8561859 ALLERGAN Dispensing device Apr, 2032

(9 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05% EMULSION;OPHTHALMIC Prescription

93. Drug name - REXULTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof Oct, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
0.25MG TABLET;ORAL Prescription
0.5MG TABLET;ORAL Prescription
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription

94. Drug name - SAXENDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen Feb, 2032

(9 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen Aug, 2032

(9 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

95. Drug name - SINUVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8763222 INTERSECT ENT INC Methods and devices for crimping self-expanding devices Feb, 2032

(9 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage
Strength Dosage Availability
1.35MG IMPLANT;IMPLANTATION Prescription

96. Drug name - STIVARGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

97. Drug name - STRIBILD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;300MG TABLET;ORAL Prescription

98. Drug name - SUBLOCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921387 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jan, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Treatment: Treating opioid dependency by administering buprenorphine once per month; treating opioid dependence by administering buprenorphine

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
100MG/0.5ML (100MG/0.5ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription
300MG/1.5ML (200MG/ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

99. Drug name - SYMTUZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

EP2744810B1 JANSSEN PRODS Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

EP2744810A1 JANSSEN PRODS Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;800MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

100. Drug name - SYNJARDY XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions Mar, 2032

(9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
12.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
25MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

101. Drug name - TAGRISSO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(9 years from now)

CN105254616B ASTRAZENECA Substituted N - (2-Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN105348266B ASTRAZENECA Substituted 3-Chloro-N - (3 - (Pyrimidin - -2 - Ylamino) Phenyl] Propanamide Or A Salt Thereof
Jul, 2032

(9 years from now)

CN103702990A ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN104109151B ASTRAZENECA N - (2 - (2-Methylamino)--4 - Methoxy - -5-[4 - (1-Methyl-Indole - -3 - Yl) Pyrimidine - -2 - Yl] Amino} Phenyl) -2 - Acrylamide Mesylate Polymorph
Jul, 2032

(9 years from now)

CN105254616A ASTRAZENECA Substituted N-(2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN104109161A ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN105175396B ASTRAZENECA Substituted 4-Methoxy -N3-(Pyrimidin - -2 - Yl) Phenyl]--1, 3-Diamine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN105348266A ASTRAZENECA Substituted 3-Chlorine-N-[3-(Pyridine--2-Ylamino) Phenyl] Propanamide Or Salt
Jul, 2032

(9 years from now)

CN104109161B ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN104109151A ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN105198862A ASTRAZENECA Substituted N-(4-Fluorin--2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN105175396A ASTRAZENECA A Substituted 4-Methoxy-N3-(Pyridine--2-Yl) Benzene-1, 3-Diamine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN105198862B ASTRAZENECA Substituted N - (4-Fluoro - -2 - Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN103702990B ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

IN297581B ASTRAZENECA 2 - (2, 4, 5 - Substituted -Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3009431A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3009431B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3686194A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

EP2736895B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3333161B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3333161A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP2736895A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3686193B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

EP3686194B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

EP3686193A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription
EQ 80MG BASE TABLET;ORAL Prescription

102. Drug name - TASIGNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity Oct, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription
EQ 200MG BASE CAPSULE;ORAL Prescription

103. Drug name - TAVALISSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8771648 RIGEL PHARMS INC (Trimethoxyphenylamino) pyrimidinyl formulations Jul, 2032

(9 years from now)

US8951504 RIGEL PHARMS INC (trimethoxyphenylamino) pyrimidinyl formulations Jul, 2032

(9 years from now)

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

104. Drug name - TAZVERIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9090562 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US8410088 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US11052093 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

CN104080769B EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compound
Apr, 2032

(9 years from now)

CN104080769A EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compound
Apr, 2032

(9 years from now)

CN107311921B EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compounds
Apr, 2032

(9 years from now)

CN107311921A EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compound
Apr, 2032

(9 years from now)

IN337354B EPIZYME INC Aryl-Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3150580A1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP2697199B1 EPIZYME INC Aryl-Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3150580B1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP2697199A1 EPIZYME INC Aryl-Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3486234B1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3486234A1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549931 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US10155002 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US8765732 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US9522152 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US10420775 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US9855275 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

105. Drug name - TECHNIVIE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
12.5MG;75MG;50MG TABLET;ORAL Discontinued

106. Drug name - TORISEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer May, 2032

(9 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer Nov, 2032

(10 years from now)

Drugs and Companies using TEMSIROLIMUS ingredient

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
25MG/ML (25MG/ML) SOLUTION;INTRAVENOUS Prescription

107. Drug name - TRIJARDY XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions Mar, 2032

(9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
12.5MG;2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
25MG;5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

108. Drug name - TRINTELLIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity Mar, 2032

(9 years from now)

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Treatment: Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Prescription

109. Drug name - TRUDHESA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550036 IMPEL NEUROPHARMA Nasal drug delivery device Sep, 2032

(9 years from now)

US10507295 IMPEL NEUROPHARMA Nasal drug delivery device Dec, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
0.725MG/SPRAY SPRAY, METERED;NASAL Prescription

110. Drug name - TRULANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

111. Drug name - TUKYSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor Oct, 2032

(10 years from now)

Drugs and Companies using TUCATINIB ingredient

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription

112. Drug name - TUXARIN ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107921 MAINPOINTE Oral dosage forms for oxygen containing active agents and oxyl-containing polymers Jan, 2032

(9 years from now)

US9066942 MAINPOINTE Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer Jan, 2032

(9 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient

Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG;54.3MG TABLET, EXTENDED RELEASE;ORAL Prescription

113. Drug name - TYBOST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct, 2032

(10 years from now)

Drugs and Companies using COBICISTAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

114. Drug name - UBRELVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

Drugs and Companies using UBROGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

115. Drug name - VARITHENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9480652 PROVENSIS Aerosol valve May, 2032

(9 years from now)

Drugs and Companies using POLIDOCANOL ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
77.5MG/7.75ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription
180MG/18ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

116. Drug name - VARUBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists Jul, 2032

(9 years from now)

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) EMULSION;INTRAVENOUS Discontinued

117. Drug name - VAZALORE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9226892 PLX PHARMA pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same Sep, 2032

(9 years from now)

US9216150 PLX PHARMA pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same Sep, 2032

(9 years from now)

Drugs and Companies using ASPIRIN ingredient

Treatment: Treatment/prevention of cardiovascular disease; temporary relief of minor aches and pains; temporary reduction of fever

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
81MG CAPSULE;ORAL Over the counter
325MG CAPSULE;ORAL Over the counter

118. Drug name - VEMLIDY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

EP2744810B1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

EP2744810A1 GILEAD SCIENCES INC Tenofovir Alafenamide Hemifumarate
Aug, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription

119. Drug name - VENCLEXTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8722657 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(9 years from now)

Drugs and Companies using VENETOCLAX ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

120. Drug name - VERQUVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604948 MERCK SHARP DOHME Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Nov, 2032

(10 years from now)

CN104159898A MERCK SHARP DOHME A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound
Nov, 2032

(10 years from now)

CN105503867B MERCK SHARP DOHME A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound
Nov, 2032

(10 years from now)

CN104159898B MERCK SHARP DOHME A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound
Nov, 2032

(10 years from now)

CN105503867A MERCK SHARP DOHME Method For Preparing Substituted 5-Fluorin--1H-Pyrromonazole Series Compound
Nov, 2032

(10 years from now)

IN384641B MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

IN201403692P1 MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

IN201818031789A MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

IN303187B MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

EP3421470B1 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form
Nov, 2032

(10 years from now)

EP2896617A1 MERCK SHARP DOHME Method For Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes
Nov, 2032

(10 years from now)

EP3421470A1 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form
Nov, 2032

(10 years from now)

EP3421470B8 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form
Nov, 2032

(10 years from now)

EP2782914A1 MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

EP2896617B1 MERCK SHARP DOHME Method For Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes
Nov, 2032

(10 years from now)

EP2782914B1 MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

Drugs and Companies using VERICIGUAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

121. Drug name - VICTOZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button Sep, 2032

(9 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

122. Drug name - VIEKIRA PAK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492386 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8685984 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Treatment: Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE;12.5MG, 75MG, 50MG TABLET;ORAL Discontinued

123. Drug name - VIEKIRA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10201541 ABBVIE INC Compositions and methods for treating HCV May, 2032

(9 years from now)

US10201584 ABBVIE INC Compositions and methods for treating HCV May, 2032

(9 years from now)

US8492386 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8685984 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE;8.33MG;50MG;33.33MG TABLET, EXTENDED RELEASE;ORAL Discontinued

124. Drug name - VOSEVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

CN103328480A GILEAD SCIENCES INC A Imidazole Imidazole For Condensation Of Antiviral Composition
Nov, 2032

(10 years from now)

CN105837584A GILEAD SCIENCES INC Condensed Imidazolyl-Imidazole As Antiviral Compound
Nov, 2032

(10 years from now)

CN105837584B GILEAD SCIENCES INC Condensation Of Imidazole Imidazole As Antivirus Compound
Nov, 2032

(10 years from now)

CN103328480B GILEAD SCIENCES INC Condensed Imidazolyl-Imidazole As Antiviral Compound
Nov, 2032

(10 years from now)

EP2907816A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2635588A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP3431477B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2907816B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP3431477A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2635588B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

More Information on Dosage
Strength Dosage Availability
400MG;100MG;100MG TABLET;ORAL Prescription

125. Drug name - VYXEOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835492 CELATOR PHARMS Method of lyophilizing liposomes Oct, 2032

(10 years from now)

US10166184 CELATOR PHARMS Method of lyophilizing liposomes Oct, 2032

(10 years from now)

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG;44MG POWDER;INTRAVENOUS Prescription

126. Drug name - XARTEMIS XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992975 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia May, 2032

(9 years from now)

US9050335 MALLINCKRODT INC Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia May, 2032

(9 years from now)

US8658631 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia May, 2032

(9 years from now)

US8741885 MALLINCKRODT INC Gastric retentive extended release pharmaceutical compositions May, 2032

(9 years from now)

US9468636 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia May, 2032

(9 years from now)

Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of acute pain in patients requiring opioid analgesia

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
325MG;7.5MG TABLET, EXTENDED RELEASE;ORAL Discontinued

127. Drug name - XEPI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180200 FERRER INTERNACIONAL Pharmaceutical topical compositions Jan, 2032

(9 years from now)

Drugs and Companies using OZENOXACIN ingredient

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

128. Drug name - XPOVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9714226 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US8999996 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Sep, 2032

(9 years from now)

CN106083827A KARYOPHARM THERAPS Transport Regulator And Use Thereof Containing A Hydrazide
Jul, 2032

(9 years from now)

CN103874690A KARYOPHARM THERAPS Transport Regulator And Use Thereof Containing A Hydrazide
Jul, 2032

(9 years from now)

CN103874690B KARYOPHARM THERAPS Transport Regulator And Use Thereof Containing A Hydrazide
Jul, 2032

(9 years from now)

CN103842340A KARYOPHARM THERAPS Nuclear Transport Modulatiors And Uses Thereof
Jul, 2032

(9 years from now)

CN106083827B KARYOPHARM THERAPS Nuclear Transport Modulators And Use Of Hydrazide-Containing
Jul, 2032

(9 years from now)

CN103842340B KARYOPHARM THERAPS Nuclear Transport Modulatiors And Uses Thereof
Jul, 2032

(9 years from now)

IN201401189P1 KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

IN361872B KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736883A1 KARYOPHARM THERAPS Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736883B1 KARYOPHARM THERAPS Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736887A1 KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736887B1 KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079865 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof Jul, 2032

(9 years from now)

US10544108 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof Jul, 2032

(9 years from now)

US11034660 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof Jul, 2032

(9 years from now)

Drugs and Companies using SELINEXOR ingredient

Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

129. Drug name - ZECUITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system Oct, 2032

(10 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof

Dosage: SYSTEM;IONTOPHORESIS

More Information on Dosage
Strength Dosage Availability
EQ 6.5MG BASE/4HR SYSTEM;IONTOPHORESIS Discontinued

130. Drug name - ZELBORAF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9447089 HOFFMANN LA ROCHE Compositions and uses thereof Jun, 2032

(9 years from now)

More Information on Dosage
Strength Dosage Availability
240MG TABLET;ORAL Prescription

131. Drug name - ZERBAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections Sep, 2032

(9 years from now)

US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections Sep, 2032

(9 years from now)

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

Treatment: Treatment of ventilator-associated bacterial pneumonia; treatment of hospital-acquired bacterial pneumonia

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL POWDER;INTRAVENOUS Prescription

132. Drug name - ZERVIATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254286 EYEVANCE Ophthalmic formulations of cetirizine and methods of use Jul, 2032

(9 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.24% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

133. Drug name - ZOLPIMIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8236285 AYTU Buccal, polar and non-polar spray containing zolpidem
Aug, 2032

(9 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/SPRAY SPRAY, METERED;ORAL Prescription

134. Drug name - ZUBSOLV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020387 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US10946010 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US8940330 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US9439900 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US9259421 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US11020388 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US10874661 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of zubsolv for treatment of opioid dependence

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.7MG BASE;EQ 0.18MG BASE TABLET;SUBLINGUAL Prescription
EQ 1.4MG BASE;EQ 0.36MG BASE TABLET;SUBLINGUAL Prescription
EQ 2.9MG BASE;EQ 0.71MG BASE TABLET;SUBLINGUAL Prescription
EQ 5.7MG BASE;EQ 1.4MG BASE TABLET;SUBLINGUAL Prescription
EQ 8.6MG BASE;EQ 2.1MG BASE TABLET;SUBLINGUAL Prescription
EQ 11.4MG BASE;EQ 2.9MG BASE TABLET;SUBLINGUAL Prescription

135. Drug name - ZURAMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(9 years from now)

Drugs and Companies using LESINURAD ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Discontinued

136. Drug name - ZYKADIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703787 NOVARTIS Methods of using ALK inhibitors Feb, 2032

(9 years from now)